An interventional study of Consulting with PARKINSUN as communication aid-tool and Consulting without PARKINSUN as communication aid-tool in Parkinson's Disease, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by University Hospital, Lille · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Parkinson Disease by University Hospital, Lille — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · University Hospital, Lille.
Among the 17 studies in Parkinson Disease by University Hospital, Lille, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2020, is one of 5 with no phase, and was the 12th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →1 of the 17 studies in Parkinson Disease by University Hospital, Lille is open now, in 1 country.
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 2 · Phase 4 2
First in 2009; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 55 across the 12 interventional studies, 158 across the 5 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Lille is the lead sponsor of 631 studies on the registry; 142 are open to participants now.
1 of the studies in Parkinson Disease by University Hospital, Lille that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04179695University Hospital, LilleEvaluation of a New Communication Aid Tool to Favor Global Patient Centered Care | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Parkinson Disease by University Hospital, Lille, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
PARKINSUN is a new communication aid tool, expected to favor global patient centered care for PD patients during consultation with GPs and neurologists. Two groups of patients will be randomized to use or not PARKINSUN when they consult their physicians every 3 months during 7 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Consulting with PARKINSUN as communication aid-tool
Other: Consulting without PARKINSUN as communication aid-tool
Participating patients visit their general practitioner or neurologist with PARKINSUN at 1 months, 4 months, 7 months
Participating patients visit their general practitioner or neurologist without PARKINSUN at 1 months, 4 months, 7 months
variation of the delta of G-MISS Questionnaire
Time frame: at 7 months
G-MISS-Questionnaire at the end of each consultation (1 month, 4 months and 7 months)
Patient's satisfaction will be assessed by the G-MISS-Questionnaire. The G-MISS questionnaire is a standardized and validated tool in French. This questionnaire is taken from the American MISS-21 questionnaire, already used in neurologists to measure the satisfaction of patients with PD, after consultation It is easy to use with an average filling time of 6 minutes.
Time frame: at the end of each consultation (1 month and 7 months)
Global score of PARKINSUN
Time frame: at the end of each consultation ((1 month and 7 months)
Individuals scores of PARKINSUN
Time frame: at the end of each consultation ((1 month and 7 months)
MDS-UPDRS scores
Time frame: at the end of each consultation ((1 month and 7 months)
PDQ-39 scores 6. Interpersonal Reactivity Index (IRI)
Time frame: at the end of each consultation ((1 month and 7 months)
Likert Scale
Time frame: at the end of each consultation (1 month and 7 months)
Interpersonal Reactivity Index (IRI)
Time frame: at the end of each consultation (1 month and 7 months)
Started Jul 2020 (actual). Primary completion is estimated for Dec 2026, 77 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 77 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.